{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T15:47:44Z","timestamp":1791820064517,"version":"4.3.4"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"vor","delay-in-days":88,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-026-07110-0","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T15:54:37Z","timestamp":1784217277000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Multidisciplinary approach to managing GPRC5D-related adverse events in relapsed or refractory multiple myeloma patients"],"prefix":"10.1007","volume":"105","author":[{"given":"Nicolas","family":"Albrecht","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eline","family":"Boeckx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo","family":"Caers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Delaunois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Delforge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorien","family":"Deneve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1284-5382","authenticated-orcid":false,"given":"Nicolas","family":"Kint","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Meuleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Sarrazyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rik","family":"Schots","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anneleen","family":"Vanhellemont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Christiane","family":"Vekemans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,16]]},"reference":[{"key":"7110_CR1","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1002\/ajh.25876","volume":"95","author":"SV Rajkumar","year":"2020","unstructured":"Rajkumar SV (2020) Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Am J Hematol 95:548\u2013567. https:\/\/doi.org\/10.1002\/ajh.25876","journal-title":"Am J Hematol"},{"key":"7110_CR2","doi-asserted-by":"publisher","first-page":"102284","DOI":"10.1016\/j.ctrv.2021.102284","volume":"100","author":"P Rodriguez-Otero","year":"2021","unstructured":"Rodriguez-Otero P, Paiva B, San-Miguel JF (2021) Roadmap to cure multiple myeloma. Cancer Treat Rev 100:102284. https:\/\/doi.org\/10.1016\/j.ctrv.2021.102284","journal-title":"Cancer Treat Rev"},{"key":"7110_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.clml.2019.09.621","volume":"20","author":"J Mikhael","year":"2020","unstructured":"Mikhael J (2020) Treatment options for triple-class refractory multiple myeloma. Clin Lymphoma Myeloma Leuk 20:1\u20137. https:\/\/doi.org\/10.1016\/j.clml.2019.09.621","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"7110_CR4","doi-asserted-by":"publisher","first-page":"151712","DOI":"10.1016\/j.ctrv.2021.102284","volume":"40","author":"D Catamero","year":"2024","unstructured":"Catamero D, Ray C, Purcell K et al (2024) Nursing considerations for the clinical management of adverse events associated with talquetamab in patients with relapsed or refractory multiple myeloma. Semin Oncol Nurs 40:151712. https:\/\/doi.org\/10.1016\/j.ctrv.2021.102284","journal-title":"Semin Oncol Nurs"},{"key":"7110_CR5","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.clml.2024.05.003","volume":"24","author":"A Chari","year":"2024","unstructured":"Chari A, Krishnan A, Rasche L et al (2024) Clinical management of patients with relapsed\/refractory multiple myeloma treated with talquetamab. Clin Lymphoma Myeloma Leuk 24:665\u2013693e14. https:\/\/doi.org\/10.1016\/j.clml.2024.05.003","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"7110_CR6","doi-asserted-by":"publisher","first-page":"e160","DOI":"10.1016\/j.clml.2020.10.002","volume":"21","author":"M Engelhardt","year":"2021","unstructured":"Engelhardt M, Ihorst G, Singh M et al (2021) Real-World Evaluation of Health-Related Quality of Life in Patients With Multiple Myeloma From Germany. Clin Lymphoma Myeloma Leuk 21:e160\u2013e175. https:\/\/doi.org\/10.1016\/j.clml.2020.10.002","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"7110_CR7","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1182\/bloodadvances.2020003805","volume":"5","author":"CPM Verkleij","year":"2021","unstructured":"Verkleij CPM, Broekmans MEC, van Duin M et al (2021) Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma. Blood Adv 5:2196\u20132215. https:\/\/doi.org\/10.1182\/bloodadvances.2020003805","journal-title":"Blood Adv"},{"key":"7110_CR8","volume-title":"June 13\u201318) Long term efficacy and safety results from the Phase 1\/2 monumenTAL-1 study of talquetamab, a GPRC5DxCD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma","author":"L Rasche","year":"2024","unstructured":"Rasche L, Schinke C, Touzeau C et al (2024) June 13\u201318) Long term efficacy and safety results from the Phase 1\/2 monumenTAL-1 study of talquetamab, a GPRC5DxCD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma. European Hematology Association (EHA) Hybrid Congress, Madrid, Spain"},{"key":"7110_CR9","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1182\/blood.2019003342","volume":"135","author":"K Pillarisetti","year":"2020","unstructured":"Pillarisetti K, Edavettal S, Mendon\u00e7a M et al (2020) A T-cell-redirecting bispecific G-protein-coupled receptor class 5 member D x CD3 antibody to treat multiple myeloma. Blood 135:1232\u20131243. https:\/\/doi.org\/10.1182\/blood.2019003342","journal-title":"Blood"},{"key":"7110_CR10","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1182\/blood-2022-159707","volume":"140","author":"A Chari","year":"2022","unstructured":"Chari A, Touzeau C, Schinke C et al (2022) Talquetamab, a G protein-coupled receptor family C group 5 member D x CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma (RRMM): Phase 1\/2 results from monumenTAL-1. Blood 140:384\u2013387. https:\/\/doi.org\/10.1182\/blood-2022-159707","journal-title":"Blood"},{"key":"7110_CR11","unstructured":"European Medicines Agency (2024), Accessed 2024 TALVEY [summary of product characteristics]. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/talvey-epar-product-information_en.pdf"},{"key":"7110_CR12","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","volume":"387","author":"P Moreau","year":"2022","unstructured":"Moreau P, van de Garfall AL et al (2022) Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med 387:495\u2013505. https:\/\/doi.org\/10.1056\/NEJMoa2203478","journal-title":"N Engl J Med"},{"key":"7110_CR13","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/S0140-6736(21)01338-6","volume":"398","author":"SZ Usmani","year":"2021","unstructured":"Usmani SZ, van de Garfall AL et al (2021) Teclistamab, a B-cell maturation antigen \u00d7 CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study. Lancet 398:665\u2013674. https:\/\/doi.org\/10.1016\/S0140-6736(21)01338-6","journal-title":"Lancet"},{"key":"7110_CR14","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","volume":"29","author":"AM Lesokhin","year":"2023","unstructured":"Lesokhin AM, Tomasson MH, Arnulf B et al (2023) Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat Med 29:2259\u20132267. https:\/\/doi.org\/10.1038\/s41591-023-02528-9","journal-title":"Nat Med"},{"key":"7110_CR15","unstructured":"Schinke C, Touzeau C, Minnema MC (2023) Pivotal phase 2 monumenTAL-1 results of talquetamab, a GPRC5D\u00d7CD3 bispecific antibody, for relapsed\/refractory multiple myeloma. American Society of Clinical Oncology (ASCO) Annual Meeting"},{"key":"7110_CR16","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1056\/NEJMoa2209900","volume":"387","author":"S Mailankody","year":"2022","unstructured":"Mailankody S, Devlin SM, Landa J et al (2022) GPRC5D-targeted CAR T cells for myeloma. N Engl J Med 387:1196\u20131206. https:\/\/doi.org\/10.1056\/NEJMoa2209900","journal-title":"N Engl J Med"},{"key":"7110_CR17","doi-asserted-by":"publisher","first-page":"e9863287","DOI":"10.1097\/01.HS9.0000967684.98632.87","volume":"7","author":"S Bal","year":"2023","unstructured":"Bal S, Berdeja J, Htut M et al (2023) S193: BMS-986393 (CC-95266), A G protein\u2013coupled receptor class C group member D (GPRC5D)\u2013targeted CAR T-cell therapy for relapsed\/refractory multiple myeloma (RRMM): results from a Phase 1 study. HemaSphere 7:e9863287. https:\/\/doi.org\/10.1097\/01.HS9.0000967684.98632.87","journal-title":"HemaSphere"},{"key":"7110_CR18","doi-asserted-by":"publisher","first-page":"e107","DOI":"10.1016\/S2352-3026(22)00372-6","volume":"10","author":"M Zhang","year":"2023","unstructured":"Zhang M, Wei G, Zhou L et al (2023) GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-centre, single-arm, phase 1 trial. Lancet Haematol 10:e107\u2013e116. https:\/\/doi.org\/10.1016\/S2352-3026(22)00372-6","journal-title":"Lancet Haematol"},{"key":"7110_CR19","doi-asserted-by":"crossref","unstructured":"Carlo-Stella C, Mazza R, Manier S et al (2022) RG6234, a GPRC5DxCD3 T-cell engaging bispecific antibody, is highly active in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): updated intravenous (IV) and first subcutaneous (SC) results from a Phase I dose-escalation study. ASH Annual Meeting","DOI":"10.1182\/blood-2022-157988"},{"key":"7110_CR20","doi-asserted-by":"publisher","first-page":"e205","DOI":"10.1016\/S1470-2045(24)00043-3","volume":"25","author":"P Rodriguez-Otero","year":"2024","unstructured":"Rodriguez-Otero P, Usmani S, Cohen AD et al (2024) International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma. Lancet Oncol 25:e205\u2013e216. https:\/\/doi.org\/10.1016\/S1470-2045(24)00043-3","journal-title":"Lancet Oncol"},{"key":"7110_CR21","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1046\/j.0022-202X.2004.12628.x","volume":"122","author":"S Inoue","year":"2004","unstructured":"Inoue S, Nambu T, Shimomura T (2004) The RAIG family member, GPRC5D, is associated with hard-keratinized structures. J Invest Dermatol 122:565\u2013573. https:\/\/doi.org\/10.1046\/j.0022-202X.2004.12628.x","journal-title":"J Invest Dermatol"},{"key":"7110_CR22","doi-asserted-by":"crossref","unstructured":"Goldsmith R, Cornax I, Ma JY et al (2021) P-095: normal human tissue expression of G-protein coupled receptor 5D (GPRC5D), a promising novel target for multiple myeloma, is restricted to plasma cells and hard keratinized tissues, vol 21. Clinical Lymphoma, Myeloma and Leukemia, p S91","DOI":"10.1016\/S2152-2650(21)02229-1"},{"key":"7110_CR23","doi-asserted-by":"publisher","unstructured":"Buttiron Webber T, Briata IM, DeCensi A et al (2023) Taste and smell disorders in cancer treatment: results from an integrative rapid systematic review. Int J Mol Sci 24. https:\/\/doi.org\/10.3390\/ijms24032538","DOI":"10.3390\/ijms24032538"},{"key":"7110_CR24","doi-asserted-by":"publisher","unstructured":"Munankarmi D Management of dysgeusia related to cancer: a systematic review J. Lumbini Med 5:3\u201312. https:\/\/doi.org\/10.22502\/jlmc.v5i1.110","DOI":"10.22502\/jlmc.v5i1.110"},{"key":"7110_CR25","doi-asserted-by":"publisher","first-page":"134","DOI":"10.3389\/fphys.2017.00134","volume":"8","author":"B Murtaza","year":"2017","unstructured":"Murtaza B, Hichami A, Khan AS et al (2017) Alteration in taste perception in cancer: causes and strategies of treatment. Front Physiol 8:134. https:\/\/doi.org\/10.3389\/fphys.2017.00134","journal-title":"Front Physiol"},{"key":"7110_CR26","doi-asserted-by":"publisher","unstructured":"Ponticelli E, Clari M, Frigerio S et al (2017) Dysgeusia and health-related quality of life of cancer patients receiving chemotherapy: a cross-sectional study. Eur J Cancer Care (Engl) 26. https:\/\/doi.org\/10.1111\/ecc.12633","DOI":"10.1111\/ecc.12633"},{"key":"7110_CR27","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1182\/blood.2024025987","volume":"145","author":"J Eckmann","year":"2025","unstructured":"Eckmann J, Fauti T, Biehl M et al (2025) Forimtamig, a novel GPRC5D-targeting T-cell bispecific antibody with a 2 + 1 format, for the treatment of multiple myeloma. Blood 145:202\u2013219. https:\/\/doi.org\/10.1182\/blood.2024025987","journal-title":"Blood"},{"key":"7110_CR28","doi-asserted-by":"publisher","unstructured":"Bal S, Htut M, Nadeem O, et al (2026) Arlocaptagene autoleucel, a GPRC5D-targeted CAR-T cell therapy in heaviliy pretreated relapsed\/refractory multiple myeloma. Blood. Online ahead of print. https:\/\/doi.org\/10.1182\/blood.2025030750","DOI":"10.1182\/blood.2025030750"},{"key":"7110_CR29","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau7746","author":"EL Smith","year":"2019","unstructured":"Smith EL, Harrington K, Staehr M et al (2019) GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells. Sci Transl Med 11. https:\/\/doi.org\/10.1126\/scitranslmed.aau7746","journal-title":"Sci Transl Med 11"},{"key":"7110_CR30","doi-asserted-by":"publisher","first-page":"e255","DOI":"10.1016\/S1470-2045(23)00159-6","volume":"24","author":"H Ludwig","year":"2023","unstructured":"Ludwig H, van de Terpos E et al (2023) Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network. Lancet Oncol 24:e255\u2013e269. https:\/\/doi.org\/10.1016\/S1470-2045(23)00159-6","journal-title":"Lancet Oncol"},{"key":"7110_CR31","doi-asserted-by":"publisher","first-page":"e000933","DOI":"10.1136\/esmoopen-2020-000933","volume":"5","author":"D Santini","year":"2020","unstructured":"Santini D, Armento G, Giusti R et al (2020) Management of orphan symptoms: ESMO Clinical Practice Guidelines for diagnosis and treatment. ESMO Open 5:e000933. https:\/\/doi.org\/10.1136\/esmoopen-2020-000933","journal-title":"ESMO Open"},{"key":"7110_CR32","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1111\/jtxs.12575","volume":"52","author":"J Hu","year":"2021","unstructured":"Hu J, Andablo-Reyes E, Mighell A et al (2021) Dry mouth diagnosis and saliva substitutes-a review from a textural perspective. J Texture Stud 52:141\u2013156. https:\/\/doi.org\/10.1111\/jtxs.12575","journal-title":"J Texture Stud"},{"key":"7110_CR33","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1177\/154405910508400105","volume":"84","author":"SM Heckmann","year":"2005","unstructured":"Heckmann SM, Hujoel P, Habiger S et al (2005) Zinc gluconate in the treatment of dysgeusia\u2013a randomized clinical trial. J Dent Res 84:35\u201338. https:\/\/doi.org\/10.1177\/154405910508400105","journal-title":"J Dent Res"},{"key":"7110_CR34","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","volume":"387","author":"A Chari","year":"2022","unstructured":"Chari A, Minnema MC, Berdeja JG et al (2022) Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma. N Engl J Med 387:2232\u20132244. https:\/\/doi.org\/10.1056\/NEJMoa2204591","journal-title":"N Engl J Med"},{"key":"7110_CR35","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1016\/S2352-3026(21)00283-0","volume":"9","author":"NS Raje","year":"2022","unstructured":"Raje NS, Anaissie E, Kumar SK et al (2022) Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group. Lancet Haematol 9:e143\u2013e161. https:\/\/doi.org\/10.1016\/S2352-3026(21)00283-0","journal-title":"Lancet Haematol"},{"key":"7110_CR36","doi-asserted-by":"publisher","unstructured":"Rasche L, Schinke C, Chari A et al (2023) P892: Analysis of infections and parameters of humoral immunity in patients (pts) with relapsed\/refractory multiple myeloma (RRMM) treated with talquetamab (TAL) monotherapy in monumenTAL-1. . HemaSphere 7. https:\/\/doi.org\/10.1097\/01.HS9.0000970472.64690.4e","DOI":"10.1097\/01.HS9.0000970472.64690.4e"},{"key":"7110_CR37","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2018","unstructured":"Lee DW, Santomasso BD, Locke FL et al (2018) ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transpl 25:625\u2013638. https:\/\/doi.org\/10.1016\/j.bbmt.2018.12.758","journal-title":"Biol Blood Marrow Transpl"},{"key":"7110_CR38","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1182\/blood-2016-07-730689","volume":"124","author":"DW Lee","year":"2014","unstructured":"Lee DW, Gardner R, Porter DL et al (2014) Current concepts in the diagnosis and management of cytokine release syndrome. Blood 124:188\u2013195. https:\/\/doi.org\/10.1182\/blood-2016-07-730689","journal-title":"Blood"},{"key":"7110_CR39","doi-asserted-by":"publisher","first-page":"2368","DOI":"10.3324\/haematol.2023.284436","volume":"109","author":"M Forsberg","year":"2024","unstructured":"Forsberg M, Beltran S, Goldfinger M et al (2024) Phenomenon of tumor flare with talquetamab in a patient with extramedullary myeloma. Haematologica 109:2368\u20132371. https:\/\/doi.org\/10.3324\/haematol.2023.284436","journal-title":"Haematologica"},{"key":"7110_CR40","doi-asserted-by":"publisher","unstructured":"Sandahl T, Rattu MA, Jiang G et al (2025) Management of patients with relapsed\/refractory multiple myeloma treated with talquetamab: highlights from pharmacists\u2019 perspectives. J Adv Pract Oncol 1\u201316. https:\/\/doi.org\/10.6004\/jadpro.2025.16.7.15","DOI":"10.6004\/jadpro.2025.16.7.15"},{"key":"7110_CR41","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1111\/ejh.14353","volume":"114","author":"C Labanca","year":"2025","unstructured":"Labanca C, Martino EA, Vigna E et al (2025) Talquetamab in multiple myeloma: efficacy, safety, and future directions. Eur J Haematol 114:386\u2013399. https:\/\/doi.org\/10.1111\/ejh.14353","journal-title":"Eur J Haematol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-07110-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07110-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07110-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T15:03:16Z","timestamp":1791817396000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-07110-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,16]]},"references-count":41,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,11]]}},"alternative-id":["7110"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-07110-0","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,16]]},"assertion":[{"value":"25 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The MonumenTAL-1 study was performed in line with the principles of the Declaration of Helsinki and relevant guidelines and regulations.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"451"}}